000153912 001__ 153912
000153912 005__ 20240229133153.0
000153912 0247_ $$2doi$$a10.3390/cells9030617
000153912 0247_ $$2pmid$$apmid:32143367
000153912 037__ $$aDKFZ-2020-00522
000153912 041__ $$aeng
000153912 082__ $$a570
000153912 1001_ $$aGaitantzi, Haristi$$b0
000153912 245__ $$aBMP-9 Modulates the Hepatic Responses to LPS.
000153912 260__ $$aBasel$$bMDPI$$c2020
000153912 3367_ $$2DRIVER$$aarticle
000153912 3367_ $$2DataCite$$aOutput Types/Journal article
000153912 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1611837471_16060
000153912 3367_ $$2BibTeX$$aARTICLE
000153912 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153912 3367_ $$00$$2EndNote$$aJournal Article
000153912 500__ $$aDKFZ-ZMBH Alliance
000153912 520__ $$aIt was previously shown that Bone Morphogenetic Protein (BMP)-9 is constitutively produced and secreted by hepatic stellate cells (HSC). Upon acute liver damage, BMP-9 expression is transiently down-regulated and blocking BMP-9 under conditions of chronic damage ameliorated liver fibrogenesis in C57BL/6 mice. Thereby, BMP-9 acted as a pro-fibrogenic cytokine in the liver but without directly activating isolated HSC in vitro. Lipopolysaccharide (LPS), an endotoxin derived from the membrane of Gram-negative bacteria in the gut, is known to be essential in the pathogenesis of diverse kinds of liver diseases. The aim of the present project was therefore to investigate how high levels of BMP-9 in the context of LPS signalling might result in enhanced liver damage. For this purpose, we stimulated human liver sinusoidal endothelial cells (LSEC) with LPS and incubated primary human liver myofibroblasts (MF) with the conditioned medium of these cells. We found that LPS led to the secretion of factors from LSEC that upregulate BMP-9 expression in MF. At least one of these BMP-9 enhancing factors was defined to be IL-6. High BMP-9 in turn, especially in combination with LPS stimulation, induced the expression of certain capillarization markers in LSEC and enhanced the LPS-mediated induction of pro-inflammatory cytokines in primary human macrophages. In LSEC, pre-treatment with BMP-9 reduced the LPS-mediated activation of the NfkB pathway, whereas in macrophages, LPS partially inhibited the BMP-9/Smad-1 signaling cascade. In vivo, in mice, BMP-9 led to the enhanced presence of F4/80-positive cells in the liver and it modulated the LPS-mediated regulation of inflammatory mediators. In summary, our data point to BMP-9 being a complex and highly dynamic modulator of hepatic responses to LPS: Initial effects of LPS on LSEC led to the upregulation of BMP-9 in MF but sustained high levels of BMP-9 in turn promote pro-inflammatory reactions of macrophages. Thereby, the spatial and timely fine-tuned presence (or absence) of BMP-9 is needed for efficient wound-healing responses in the liver.
000153912 536__ $$0G:(DE-HGF)POF3-321$$a321 - Basic Concepts (POF3-321)$$cPOF3-321$$fPOF III$$x0
000153912 588__ $$aDataset connected to CrossRef, PubMed,
000153912 7001_ $$aKarch, Julius$$b1
000153912 7001_ $$aGermann, Lena$$b2
000153912 7001_ $$aCai, Chen$$b3
000153912 7001_ $$aRausch, Vanessa$$b4
000153912 7001_ $$00000-0002-0338-3727$$aBirgin, Emrullah$$b5
000153912 7001_ $$aRahbari, Nuh$$b6
000153912 7001_ $$aSeitz, Tatjana$$b7
000153912 7001_ $$aHellerbrand, Claus$$b8
000153912 7001_ $$0P:(DE-He78)5ef958977fa3c0658679b496419ce762$$aKönig, Courtney$$b9
000153912 7001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b10$$udkfz
000153912 7001_ $$aMogler, Carolin$$b11
000153912 7001_ $$00000-0001-8918-2266$$ade la Torre, Carolina$$b12
000153912 7001_ $$aGretz, Norbert$$b13
000153912 7001_ $$aItzel, Timo$$b14
000153912 7001_ $$aTeufel, Andreas$$b15
000153912 7001_ $$aEbert, Matthias P A$$b16
000153912 7001_ $$00000-0002-1814-4796$$aBreitkopf-Heinlein, Katja$$b17
000153912 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells9030617$$gVol. 9, no. 3, p. 617 -$$n3$$pE617$$tCells$$v9$$x2073-4409$$y2020
000153912 909CO $$ooai:inrepo02.dkfz.de:153912$$pVDB
000153912 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef958977fa3c0658679b496419ce762$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000153912 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000153912 9131_ $$0G:(DE-HGF)POF3-321$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vBasic Concepts$$x0
000153912 9141_ $$y2020
000153912 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2017
000153912 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153912 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153912 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153912 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000153912 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000153912 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000153912 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000153912 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000153912 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153912 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153912 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153912 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153912 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153912 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153912 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153912 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastatistierung$$x0
000153912 980__ $$ajournal
000153912 980__ $$aVDB
000153912 980__ $$aI:(DE-He78)A190-20160331
000153912 980__ $$aUNRESTRICTED